Garry Menzel

Garry Menzel

Directeur/Membre du Conseil chez ADAPTIMMUNE THERAPEUTICS PLC

Fortune : 1 M $ au 30/04/2024

59 ans
Health Technology
Consumer Services
Commercial Services

Profil

Garry E.
Menzel
is currently the Director at Epilepsy Therapy Project.
He also holds current positions as an Independent Non-Executive Director at Adaptimmune Therapeutics Plc, an Independent Director at Stoke Therapeutics, Inc., an Independent Director at Black Diamond Therapeutics, Inc., a Member-National Board at Epilepsy Foundation, the Principal at Royal College of Art, and an Operating Partner at GHO Capital Partners LLP.
In his former roles, Dr. Menzel served as the President, Chief Executive Officer & Director at TCR2 Therapeutics, Inc. from 2016 to 2023.
He was also a Managing Director at Credit Suisse Group AG from 2004 to 2008 and at The Goldman Sachs Group, Inc. from 1994 to 2004.
Additionally, he held positions as the Chief Financial Officer at DaVita, Inc. from 2013 to 2015, the Chief Operating Officer at Regulus Therapeutics, Inc. from 2008 to 2013, and the Chief Strategy Officer at Axcella Health, Inc. from 2015 to 2016.
He has also worked as a Research Assistant at Smithkline Beecham Plc and as a Consultant at Bain & Co., Inc.Dr. Menzel's education includes an undergraduate degree from Imperial College London in 1985, a doctorate from the University of Cambridge, and an MBA from Stanford Graduate School of Business in 1994.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
01/04/2024 3 667 344 ( 0,65% ) 648 020 $ 30/04/2024
05/04/2024 76 664 ( 0,15% ) 391 753 $ 30/04/2024
31/03/2024 0 ( -.--% ) - $ 30/04/2024

Postes actifs de Garry Menzel

SociétésPosteDébut
BLACK DIAMOND THERAPEUTICS, INC. Directeur/Membre du Conseil 01/01/2014
STOKE THERAPEUTICS, INC. Directeur/Membre du Conseil 13/08/2020
ADAPTIMMUNE THERAPEUTICS PLC Directeur/Membre du Conseil 01/06/2023
Corporate Officer/Principal 01/01/2003
Epilepsy Therapy Project Directeur/Membre du Conseil -
Royal College of Art Corporate Officer/Principal 17/03/2010
Private Equity Investor 23/04/2024
Tous les postes actifs de Garry Menzel

Anciens postes connus de Garry Menzel

SociétésPosteFin
TCR2 THERAPEUTICS INC. Directeur Général 01/01/2023
AXCA HEALPAR Corporate Officer/Principal 01/09/2016
░░░░░░ ░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░░░░░ ░░░ ░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░ ░░░░░ ░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
Voir l'expérience en détail de Garry Menzel

Formation de Garry Menzel

Imperial College London Undergraduate Degree
Stanford Graduate School of Business Masters Business Admin
University of Cambridge Doctorate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Garry Menzel

Relations

100 +

Relations au 1er degré

19

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées7
REGULUS THERAPEUTICS INC.

Health Technology

THE GOLDMAN SACHS GROUP, INC.

Finance

DAVITA INC.

Health Services

BLACK DIAMOND THERAPEUTICS, INC.

Health Technology

AXCA HEALPAR

Health Technology

STOKE THERAPEUTICS, INC.

Health Technology

ADAPTIMMUNE THERAPEUTICS PLC

Health Technology

Entreprise privées8

Commercial Services

Commercial Services

Finance

Epilepsy Therapy Project

Health Technology

Health Technology

Commercial Services

Finance

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Garry Menzel
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT